Price T Rowe Associates Inc. MD Trims Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Price T Rowe Associates Inc. MD trimmed its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 248,264 shares of the company's stock after selling 25,367 shares during the period. Price T Rowe Associates Inc. MD's holdings in Roivant Sciences were worth $2,937,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ROIV. Treasurer of the State of North Carolina lifted its holdings in shares of Roivant Sciences by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 187,047 shares of the company's stock worth $2,213,000 after acquiring an additional 1,170 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Roivant Sciences by 57.0% during the 4th quarter. GAMMA Investing LLC now owns 3,548 shares of the company's stock worth $42,000 after acquiring an additional 1,288 shares during the last quarter. WINTON GROUP Ltd lifted its holdings in shares of Roivant Sciences by 1.5% during the 4th quarter. WINTON GROUP Ltd now owns 92,526 shares of the company's stock worth $1,095,000 after acquiring an additional 1,332 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Roivant Sciences by 7.5% during the 4th quarter. Covestor Ltd now owns 20,634 shares of the company's stock worth $245,000 after acquiring an additional 1,444 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Roivant Sciences by 27.0% during the 4th quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company's stock worth $84,000 after acquiring an additional 1,507 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Trading Down 3.4%

ROIV traded down $0.38 during midday trading on Friday, reaching $10.65. The company's stock had a trading volume of 6,735,679 shares, compared to its average volume of 5,566,358. The firm has a market capitalization of $7.60 billion, a price-to-earnings ratio of -71.00 and a beta of 1.23. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06. The stock's 50-day moving average is $10.49 and its 200-day moving average is $11.11.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. As a group, equities research analysts forecast that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Insider Transactions at Roivant Sciences

In related news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $10.22, for a total transaction of $1,022,000.00. Following the transaction, the chief operating officer now owns 1,116,345 shares in the company, valued at $11,409,045.90. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the transaction, the chief accounting officer now owns 163,264 shares in the company, valued at approximately $1,702,843.52. This trade represents a 58.22% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,669,500 shares of company stock worth $18,064,847. Corporate insiders own 7.90% of the company's stock.

Analyst Upgrades and Downgrades

ROIV has been the subject of several recent research reports. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Monday, April 21st.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.